The focus of this 3-day workshop is on understanding the complex causes underlying the emergence and spread of AMR, and on practical approaches to tackle antibiotic misuse in different settings.
Erika Vlieghe MD
Head of the department of General Internal Medicine, Infectious diseases and Tropical Medicine, University Hospital Antwerp
Professor of infectious diseases, University of Antwerp
Haileyesus Getahun Gebre, MD PhD MPH – AMR secretariat, WHO, Geneva
Peter J. Dailey, PhD, MPH – University of California, Berkeley
Jorg Janne Vehreschild, MD – University of Cologne
Christian Lavallée, MD – Université de Montréal
Yoshiko Nakamachi, RN, BScN, BA, PMP – University Health Network, Toronto
Cédric Yansouni, MD, FRCPC, DTM&H – McGill University
Louis-Patrick Haraoui, MD MSc – Université de Sherbrooke
Michael Libman, MD FRCP – McGill University
Faculty members are still being confirmed and there may be changes to the above list
Antimicrobial resistance (AMR) is now one the biggest threats facing modern medicine. Initially described mostly in association with hospital-associated infections in high-income countries, the highest rates of AMR are now reported from low and middle-income countries (LMIC) around the world. The causes underlying the global rise in AMR are complex, but central to this crisis is overconsumption of antibiotics.
This 3-day workshop will focus on understanding the complex causes underlying the emergence and spread of AMR, and on approaches to tackle antibiotic misuse in different settings. The workshop format is a mix of plenary talks and panel discussions, with opportunities to interact with participants who work across the spectrum of the antimicrobial resistance space in different countries.
Clinicians, researchers, implementers, and health educators from both high-income and LMIC will share questions, successes, and lessons learned to advance the field of AMR.
NOTE: Global Health Diagnostics and the Antimicrobial Resistance course will be taught together on Wednesday, June 12th.
This course appeals to a wide range of participants including:
- Clinicians, pharmacists, technologists, researchers and students studying infectious diseases, tropical medicine, or global health
- Policy makers and public health agency officials
- Product developers and funders
- Community advocacy groups working in global health
Maximum of 100 participants.